Patents by Inventor Tuula Ryde

Tuula Ryde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nanoparticulate meloxicam formulations
    Patent number: 8512727
    Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: August 20, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
  • NANOPARTICULATE MEGESTROL FORMULATIONS
    Publication number: 20120087955
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: October 7, 2011
    Publication date: April 12, 2012
    Inventors: Douglas HOVEY, John Pruitt, Tuula Ryde
  • LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
    Publication number: 20110165251
    Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 7, 2011
    Inventors: H. William BOSCH, Matthew R. HILBORN, Douglas C. HOVEY, Laura J. KLINE, Robert W. LEE, John D. PRUITT, Niels P. RYDE, Tuula A. RYDE, Shuqian XU
  • Nanoparticulate fibrate formulations
    Patent number: 7931917
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: April 26, 2011
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Nanoparticulate fibrate formulations
    Patent number: 7927627
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: April 19, 2011
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Nanoparticulate statin formulations and novel statin combinations
    Publication number: 20110027371
    Abstract: The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.
    Type: Application
    Filed: March 6, 2006
    Publication date: February 3, 2011
    Inventors: Eugene R. Cooper, Douglas Hovey, Greta Cary, Marie Lindner, Elaine Liversidge, Gary G. Liversidge, Tuula Ryde
  • NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
    Publication number: 20100329976
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 30, 2010
    Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
    Publication number: 20100322853
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 23, 2010
    Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
    Publication number: 20100322852
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 23, 2010
    Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • NANOPARTICULATE MELOXICAM FORMULATIONS
    Publication number: 20100297252
    Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: May 26, 2010
    Publication date: November 25, 2010
    Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
  • NANOPARTICULATE MEGESTROL FORMULATIONS
    Publication number: 20100266705
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: June 29, 2010
    Publication date: October 21, 2010
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Nanoparticulate megestrol formulations
    Publication number: 20100226989
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: June 22, 2006
    Publication date: September 9, 2010
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
    Publication number: 20080279949
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 13, 2008
    Inventors: Elaine MERISKO-LIVERSIDGE, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • FENOFIBRATE DOSAGE FORMS
    Publication number: 20080241070
    Abstract: Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also disclosed are in vitro methods for evaluating the in vivo effectiveness of fibrate, such as fenofibrate, dosage forms. The methods utilize media representative of in vivo human physiological conditions.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Inventors: Tuula A. Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins, Niels P. Ryde
  • NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
    Publication number: 20080226732
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: October 30, 2007
    Publication date: September 18, 2008
    Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • Nanoparticulate compositions of angiogenesis inhibitors
    Publication number: 20080220075
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: March 14, 2008
    Publication date: September 11, 2008
    Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta G. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
  • Nanoparticulate statin formulations and novel statin combinations
    Publication number: 20080213378
    Abstract: The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 4, 2008
    Inventors: Eugene R. Cooper, Douglas Hovey, Greta Cary, Marie Lindner, Elaine Liversidge, Gary G. Liversidge, Tuula Ryde
  • Nanoparticulate megestrol formulations
    Publication number: 20080171088
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 17, 2008
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Low viscosity liquid dosage forms
    Publication number: 20080152585
    Abstract: The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 26, 2008
    Inventors: Tuula Ryde, Niels Ryde, H. William Bosch, John D. Pruitt, Christian F. Wertz
  • Nanoparticulate topiramate formulations
    Patent number: 7390505
    Abstract: The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: June 24, 2008
    Assignee: Elan Pharma International, Ltd.
    Inventors: Evan Gustow, Tuula Ryde, Eugene R. Cooper